Evopoint

688837
35.212.17% ( -0.78 )
Delay Closed: Nov 16, 15:00:00

Profile

About

Evopoint
Evopoint
688837.SH

Evopoint Biosciences Co., Ltd. operates as a biopharmaceutical company that offers therapies for patients with oncology and multidrug-resistant (MDR) infections in China. It offers its three-core technology platforms, Small Molecule Drug Discovery Platform that uses multi-omics, functional screening, and a medicinal chemistry engine to create precision therapies for epigenetics, synthetic lethality, and MDR infections; Novel Antibody Discovery Platform which offers antibody therapeutics (e.g., ADCs, bispecifics, TCEs) to achieve precision and expanded therapeutic windows against refractory solid tumors like pancreatic and gastric cancer; and Targeted Protein Degradation Platform, a glue and ligase-mediated ubiquitin-dependent elimination platform. The company also has various drugs in its pipeline including XNW4107 for HABP/VABP, XNW5004 for Lymphoma & Solid Tumor; XNW27011, XNW28012, XNW29016, and XNW34017 for solid tumor and XNW1011 for autoimmune diseases.

Profile

Company Name
Evopoint Biosciences Co., Ltd.
Market
SHSE
Founded
Industry
--
Fiscal Year End
December 31

Related Securities

Industry

Management